INTRODUCTION
Inherited genetic disorders of the eye result in severe functional deficits in patients, and to date, many of these disorders have been intractable to precisionbased therapies [1, 2] . Since the first efforts to sequence the human genome, scientists and physicians have aimed to modify pathogenic genomic loci to alleviate disease burden [3] [4] [5] . Recently, with the advent of technologies for direct DNA modification, practicing precision genome surgery in ophthalmology is now closer to becoming a reality. Originally derived from the immune system of bacteria and archaea, clustered regularly interspaced short palindromic repeats (CRISPR)-associated systems (Cas) have become repurposed for DNA manipulation in biomedicine [6] . The present review seeks to highlight the use of CRISPR-Cas systems in ophthalmology, particularly over the past year.
CRISPR-Cas genome engineering
Targeting double-stranded breaks (DSBs) to the desired genomic loci has become a mainstay for the modification of eukaryotic systems [7] . These DSBs can be repaired either by a strategy known as homologydirected repair (HDR), or by nonhomologous end joining (NHEJ), an error-prone process that often results in insertions and deletions (INDELs) [8] . Over the past decade, meganucleases, zinc-finger nucleases and transcription activator-like effector nucleases have been the dominant tools for the introduction of DSBs in cells [9] . Although these tools can be used to generate precise DSBs, their engineering can be laborious and time intensive because of protein engineering considerations, among other factors [6] . In 2012 the mechanistic actions of the reprogrammable endonucleases from the CRISPR-Cas system of Streptococcus pyogenes were first elucidated in detail, and since its first implementation in human cells, the repurposing of this system for genome surgery has skyrocketed [6, [10] [11] [12] .
Because of the ease of re-engineering CRISPRCas for diverse targets, this system has become popular for genome surgery in a variety of organisms [13] [14] [15] [16] [17] [18] [19] [20] . CRISPR-Cas genome editing from the type II CRISPR system of S. pyogenes relies on the RNAguided endonuclease, Cas9 (SpCas9), and two RNA molecules, a CRISPR RNA (crRNA) and a trans-activating RNA (tracrRNA), which associate and complex with Cas9 to guide cleavage of DNA sequences based on homology between the crRNA and target DNA strand [10, 21, 22] . A chimeric molecule of the crRNA and tracrRNA was created and subsequently dubbed 'single guide RNA' (sgRNA), which was demonstrated to be as effective as the original system [10] . The sgRNA contains a 20 base pair region that binds to the homologous DNA strand. Cas9 associates with the DNA and generates a blunt cut three base pairs upstream of the protospacer adjacent motif (PAM), a three-nucleotide sequence required for Cas9 association (canonically an NGG sequence) [10, [23] [24] [25] . Although other endonucleases like the Cas9 derived from S. pyogenes have been discovered and optimized for gene editing purposes, SpCas9 has been utilized the most since its introduction [6] .
SpCas9 has been further modified to attenuate its cutting ability to that of a nickase (SpCas9D10A), wherein the enzyme is only able to induce a singlestranded break rather than a DSB [26, 27] . SpCas9 has also been modified to completely remove its nuclease activity (termed dCas9 for 'catalytically dead Cas9') to allow for activator and repressor protein fusions [26, 27] . Because of the versatile applications of SpCas9 to edit, activate, repress and even epigenetically modify DNA in vivo, CRISPR-Cas systems have become essential tools in biotechnology [26, [28] [29] [30] [31] [32] (Fig. 1a-e) . Recently, Komor et al. [33] developed dCas9-deaminase and Cas9-nickasedeaminase fusions capable of inducing cytidine to uridine transitions and allowing for directed mutagenesis without introducing a DSB (Fig. 1f) .
Off-target binding of Cas enzymes are important considerations, especially when the generation of precise modifications is essential, as it is in clinical situations [34] . Although there are several softwares available to predict off-target binding of RNAguided endonucleases using sgRNA target sequences and the host genome, a recent experimental study by Tsai et al. [35] showed that there is variability in predicted and experimentally verified off-target binding sites. This suggests that examining off-target modifications via CRISPR-Cas in a clinical setting is crucial.
CRISPR-Cas genome editing in mammalian preclinical models of the eye
The ease, reduced cost and rapid speed of generating novel RNA-guided endonucleases have revolutionized the generation of animal models [15, 36] . Recently, Wu et al. used CRISPR-Cas genome editing to untangle the effects of two potentially pathogenic genetic differences in 'rodless' (rd1, Pde6b rd1 / Pde6b rd1 ) mice, an important preclinical model for retinitis pigmentosa [37 & ]. These rd1 mice exhibit premature rod neuronal death believed to be a result of mutations in the Pde6b gene, which regulates intracellular cGMP levels [38, 39] . The rd1 mouse genome contains a nonsense mutation (Y347X) in the Pde6b gene and an insertion of a murine leukemia virus (Xmv-28) into intron 1 of Pde6b. It was unclear if the Xmv-28 insertion contributed to the rd1 phenotype, so the group used CRISPR-Cas genome editing, utilizing a single-stranded oligonucleotide as the donor template, to generate mice with a repaired Y347X nonsense mutation in Pde6b rd1 /Pde6b rd1 homozygous mice, the background still containing the Xmv-28 insertion. Using fundoscopy, electroretinography, optical coherence tomography and hematoxylin and eosin staining, the group showed that the wild type phenotype KEY POINTS CRISPR-Cas genome surgery can make precise modifications in mammalian and nonmammalian preclinical models of eye disease and development.
Targeting autosomal dominant mutations clinically may be especially effective because the process does not require a corrected version of the gene.
Delivery of CRISPR-Cas components via AAV vectors is effective in model systems.
Ex-vivo genome surgery to correct mutations of patientderived iPSCs and ESCs for future re-implantation is a promising therapeutic.
could be restored by repairing the Y347X nonsense mutation alone, suggesting that the Xmv-28 viral insertion is benign.
CRISPR-Cas genome editing has also been used to generate mosaic tissue models of disease. The Kcnj13 gene encodes the apically localized, retinal pigment epithelial (RPE)-specific potassium channel subunit Kir7.1. Mutations in this channel are associated with Leber Congenital Amaurosis, and in mice, homozygous null mutants of Kcnj13 result in postnatal lethality [40 && ]. Classically, scientists have employed Cre-lox systems to knock out essential genes in adult multicellular organisms and study the resulting phenotype. Briefly, the Cre-lox system enables site-specific recombination at genes of interest that have been modified to contain loxP sites flanking their 5' and 3' ends, and it concurrently requires the introduction of a transgenic Cre recombinase. Genes can then be excised via endogenous or exogenous induction of the recombinase [41] . However, generation of Cre-lox systems in mice can take at least one year. To avoid this delay, Zhong et al. [40 && ,42] took advantage of the heterogeneity of the mutations generated by NHEJ. After injection of sgRNA and SpCas9 mRNA into mouse zygotes, the developed animals exhibited tissue mosaicism with respect to the Kcnj13 locus based on tail genotyping, which is indicative of mosaicism within the retina as well. This model allowed the investigators to study the effects of a loss of function of KCNJ13 at a tissue level, which they concluded correlated with loss of photoreceptors and rhodopsin mislocalization. By employing a model that utilized NHEJ-induced mosaicism instead of conventional knockout via a Cre-loxP system, the generation of CRISPR mice was much more rapid, and diverse genotypes could be examined simultaneously.
Conversely, CRISPR-Cas genome editing can be used to make precise, single base pair changes. To assess the effects of the rs2279744 single nucleotide polymorphism (SNP) implicated in retinal detachment and carcinogenesis in proliferative vitreoretinopathy, Duan et al. exploited CRISPR genome editing. They induced the SNP, a T309G mutation in Mdm2 (murine double minute 2, an implicated inhibitory regulator of p53), into human primary RPE (hPRPE) cells in vitro [43 systems to generate human SNPs in vivo is a powerful method for screening pathogenicity, a platform that will be used increasingly more with the popularization of personalized medicine paradigms [44, 45] .
In addition, other groups have used CRISPR-Cas systems to knockout genes in parallel with shortinterfering RNA (siRNA), which are short ($20-30 nucleotides), noncoding RNA sequences that can be designed to repress the expression of genes of interest [46, 47] . Priglinger et al. [48] used CRISPR-Cas genome editing to study key processes involved in the epithelial-to-mesenchymal transition of RPE. This transition is a crucial step in proliferative vitreoretinopathy, and understanding its mechanism is essential for developing therapeutics [49] . The investigators found that CRISPR-Cas-induced knockout of b1,6-N-acetylglucosaminyltransferase V (MGAT5) in human RPE cells, along with siRNA knockdown in a separate experiment, decreased the binding of galectin-3 (Gal-3) to glycans on RPE cells in vitro. Gal-3 is an important modulator of RPE growth in vivo, and this binding modulation provided by MGAT5 makes it an interesting target for therapy [48] . This study shows the use of CRISPRCas genome surgery as a parallel tool to classic techniques such as siRNA knockdown.
Advances in ocular genetics using CRISPRCas genome editing in zebrafish
In addition to mouse and human tissue, zebrafish represent an attractive model for human disease because of their rapid lifecycle ease of manipulation, and highly orthologous correlation with human genes [50] . CRISPR-Cas genome editing has previously been applied to zebrafish [20] . Yin et al. [51] used retina tissue-specific delivery (injection and electroporation) of sgRNA targeted to the zebrafish retinal regeneration gene Ascl1a in a strain background constitutively expressing SpCas9. Targeting Ascl1a for cleavage resulted in a reduction of retinal proliferation compared with controls, as expected [52] . This study shows that spatial and temporal delivery and expression of CRISPR components are a powerful way to regulate gene activity in zebrafish, especially when targeting small cell populations in specific tissues such as the eye.
Zebrafish are a powerful model for studying development. Taylor et al. [53] induced mutations in the gene NeuroD, a potential player in retinal regeneration in zebrafish, via CRISPR-Cas genome editing. The group targeted NeuroD using sgRNA and SpCas9 to induce deleterious mutations in zebrafish embryos, and they also suppressed the gene using morpholinos oligonucleotides to provide a point of comparison. Their data suggested that NeuroD is a regulator of Notch signalling, confirming its important role in photoreceptor regeneration [53] . By using both classical genetic techniques such as morpholino knockdown and CRISPR-Cas genome editing, the findings of this study were strengthened by the rigorous experimental design.
Targeting dominant-negative alleles using CRISPR-Cas in vivo
Mismatch in the 20 base pair target sequences of the sgRNA can have severe effects on SpCas9 cleavage, especially if the mismatch occurs in the 12 base pair sequence closest to the PAM (seed sequence) [54] . In addition, alterations in the PAM sequence from canonically acceptable sequences can ablate cutting ability. Courtney et al. [55] used this characteristic of sgRNA-SpCas9 complexes to specifically target the C395T mutation in the KRT12 gene, a dominantnegative allele for Meesmann epithelial corneal dysplasia (MECD) in heterozygous patients. This particular SNP results in a novel PAM sequence which the investigators targeted with a sgRNA. Their goal was to either induce inactivating mutations (nonsense or frameshift mutations) via NHEJ or correct the allele using the wild type sequence.
After validation of sgRNA activity in vitro, the investigators used intrastromal injection of sgRNA and SpCas9-GFP plasmids to target the SNP in a humanized heterozygous mouse model of MECD. The Krt12 locus was then amplified from the treated mice, and of the 13 sequences that were analyzed, five contained NHEJ-derived mutations, four of which resulted in early termination of the pathogenic allele. This study illuminates the potential of CRISPR-Cas genome editing to not only insert beneficial alleles, but also to inactivate deleterious ones.
Bakondi et al. have applied a similar approach to ablate the autosomal dominant Rho S334 allele in a retinitis pigmentosa rat model, a mutant allele that results in misprocessing of the RHO protein and apoptotic death of photoreceptors. The Rho S334 allele contains a novel PAM sequence which the investigators targeted with a sgRNA that was first tested in vitro for targeting efficacy. sgRNA and SpCas9 plasmids were introduced via subretinal injection and electroporated to stimulate uptake into photoreceptors. Two rats in the study showed an INDEL frequency of 33 and 36% as a result of NHEJ in the Rho S334 locus. In the CRISPR-Cas ablated Rho S334 rats, the authors reported a 53% increase in visual acuity as assessed by the optokinetic behavioral response and a 35% increase in visual acuity using untreated contralateral eyes as controls within individuals. Finally, the investigators reported a nine-fold increase in nuclei density in photoreceptors at P33 [56 && ]. These beneficial effects, both functionally and histologically, of pathogenic allele ablation further support the use of CRISPR-Cas for therapies that require the removal of dominantnegative alleles (Fig. 2a and b) .
In-vivo delivery of CRISPR-Cas systems
Direct delivery of CRISPR-Cas components to retinal tissue for genome surgery in patients is an important goal that is still being studied and pursued. To this end, Hung et al. examined the efficacy of dual AAV delivery of SpCas9 and validated yellow fluorescent protein (YFP)-targeted guide RNA components were introduced into Thy1::YFP adult transgenic mice via intravitreal injections [57 & ]. These mice have a YFP gene inserted into the Thy1 locus, and CRISPR-Cas induced cleavage and the error-prone NHEJ repair would result in a decrease in functional YFP expression. Post-delivery, the group found an 84% reduction in YFP expression in cells that contained YFP-sgRNA constructs as compared to a noncutting sgRNA control. Using whole retinal mounts, the group could determine the efficacy of knockout across retinal layers, with AAV2 transduction being the greatest in retinal ganglion cells (RGCs). Without selection for sgRNA-containing cells, there was a 50% reduction in YFP expression in RGCs. Using electroretinography, no significant retinal changes could be observed 5 weeks posttransduction, indicating a lack of toxicity to CRISPR components. Recently, delivery of CRISPR-Cas components in vivo and modification of endogenous loci has been successful with varying degrees of efficacy [58] [59] [60] [61] [62] [63] . Similarly, AAV delivery of therapeutic DNA to eye tissue has been increasingly promising due to tropism preferences of AAV and the immune status of the eye [64] [65] [66] . This study shows the potential of in vivo genome engineering in adult animal retina, a technique that will likely become more translationally relevant in the near future.
Modification of stem cells using CRISPR-Cas genome editing
Patient-specific induced pluripotent stem cells (iPSCs) may be an ideal source of autologous cells to ameliorate many diseases [67] [68] [69] [70] [71] . Bassuk et al.
showed that CRISPR-Cas genome editing could be used to correct a novel mutation in the retinitis pigmentosa GTPase regulator (RPGR) locus (c.3070G > T, pGlu1024X) which results in a relatively severe X-linked RP phenotype [72 && ]. Using skin-punch biopsy, cells were collected then transformed into iPSCs, which have the potential to be differentiated into retinal cells. Because of the high GC content and repetition in the locus, 21 sgRNA constructs were tested in vitro, and one was chosen based on specificity and efficacy (sgRNA g58). Patient-derived iPSCs were modified via transfection of SpCas9, sgRNA g58, and a WT RPGR anti-sense, single-stranded oligonucleotide donor, resulting in 13% of the cells containing the corrected allele. Although not completed in this study, correctly differentiated iPSCs could theoretically be autologously transplanted back into patients.
Human embryonic stem cells (hESCs) also serve as a potential source of cells for allotransplantation, in addition to representing important tools for studying human development. Sluch et al. [73, 74] sought to ease the isolation of hESC-derived RGCs by using CRISPR-Cas genome editing to link mCherry, a red fluorescent protein that enables genome engineering to be visualized (among other purposes), to the BRN3B gene (an important marker for RGCs) using a P2A self-cleaving peptide linker in h7 hESCs. The group first targeted the stop codon of BRN3B by electroporation of sgRNA with spCas9 plasmids and an mCherry gene containing a 5' P2A linker with homology arms to the cut locus. The cell line was then differentiated to RGCs and then sorted by flow cytometry using the mCherry reporter. The mCherry-enriched cells were then analyzed for markers of RGCs via real-time quantitative PCR, used to quantitatively measure DNA amplification over time, and fluorescence staining. Ultrastructural and electrophysiological properties, assayed by transmission electron microscopy and whole-cell current clamp, respectively, further confirmed RGCs phenotype. The investigators also examined the frequency of off-target mutation at predicted sites and were unable to find off-target mutagenesis. In summary, tagging of a marker of RGC lineage using CRISPR-Cas editing allowed for rapid isolation of RGCs derived from hESCs.
CONCLUSION
CRISPR-Cas-derived tools will continue to revolutionize modern biology. In ophthalmology, these tools allow for exquisite manipulation of the genomic content in ocular cells. Because of the power of precision medicine, it is likely that the pace at which both mammalian and nonmammalian models for eye disease are used to test other therapeutics in patient-specific backgrounds will increase greatly, finally allowing for treatment plans that are tailored to each patient and genetically informed. As patient safety is at the utmost importance, vigorous screening for off-targets using experimental methods may be strongly encouraged before implantation of CRISPR-Cas edited cells to avoid off-target mutations resulting in malignant or ineffective transplants. Assuming these safeguards are in place, CRISPR-Cas technologies have great potential to benefit countless patients with inherited retinal dystrophies.
